EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Growth Differentiation Factor-15 and the Effect of Dapagliflozin in Heart Failure: Insights From the DAPA-HF Trial

David D Berg, Kieran F Docherty, Atefeh Talebi, Naveed Sattar, Petr Jarolim, Paul Welsh, Pardeep S Jhund, Inderjit S Anand, Rudolf A DE Boer, Eri T Kato, Lars Kober, Felipe A Martinez und 8 weitere

Journal of Cardiac Failure · 2026-04 · 32 (4) · 746-757

DOI: 10.1016/j.cardfail.2025.07.019 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cardiac Failure, 2026-04. Verfasst von David D Berg und 19 weiteren Autor:innen. Beteiligte Einrichtung: TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Cardiovascu…. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Growth Differentiation Factor 15, Heart Failure. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca PLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Growth differentiation factor (GDF)-15, a stress-induced cytokine implicated in systemic energy homeostasis, is associated with adverse outcomes in heart failure (HF). This study evaluated the associations between baseline GDF-15 and the clinical characteristics and outcomes in patients with HF with reduced ejection fraction in the DAPA-HF (Dapagliflozin and Prevention of Adverse-outcomes in Heart Failure) trial. The effect of the sodium-glucose cotransporter-2 inhibitor dapagliflozin on circulating GDF-15 levels and the effect of dapagliflozin on clinical outcomes in relation to baseline GDF-15 concentrations were also examined. METHODS AND RESULTS: DAPA-HF was a randomized trial of dapagliflozin in patients with HF and LVEF ≤ 40%. GDF-15 was measured at baseline and 12 months. The primary outcome was the composite of worsening HF or cardiovascular death. The median baseline GDF-15 level was 1888 (IQR: 1323-2755) pg/mL. Higher GDF-15 levels were associated with older age, lower body mass index, and greater HF symptom burden. There was a stepwise increase in adjusted risk for the primary outcome across quartiles of baseline GDF-15 (adjusted hazard ratio [Q4 vs Q1] 2.30, 95% CI 1.66-18; P trend < 0.001). Dapagliflozin did not significantly change GDF-15 concentrations over 12 months, compared to placebo (placebo-corrected relative change +4%; 95% CI, -2% to +10%). The relative effect of dapagliflozin on the primary outcome was consistent across GDF-15 quartiles (P interaction = 0.96), with a greater absolute benefit in those with higher GDF-15 (P trend < 0.01). CONCLUSIONS: In DAPA-HF, GDF-15 was independently prognostic of worsening HF or cardiovascular death. Absolute risk reduction with dapagliflozin was greater in patients with higher baseline GDF-15, but the benefit was not associated with an effect on GDF-15 itself.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsGlucosidesGrowth Differentiation Factor 15Heart FailureHumansMaleFemaleAgedSodium-Glucose Transporter 2 InhibitorsMiddle AgedBiomarkersTreatment OutcomeStroke VolumeFollow-Up Studies

Stichwörter der Autor:innen

Growth differentiation factor-15 (GDF-15)biomarkersclinical trialsheart failuresodium-glucose contransporter-2 inhibitor

Substanzen

Benzhydryl CompoundsdapagliflozinGlucosidesGrowth Differentiation Factor 15Sodium-Glucose Transporter 2 InhibitorsBiomarkersGDF15 protein, human

Autor:innen und Institutionen

  • TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Bo…
  • British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland.
  • Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • University of Minnesota, Minneapolis, MN, USA.
  • Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Department of Cardiovascular Medicine and Clinical Laboratory Department, Kyoto University Hospital, Kyoto, Japan.

Förderung

  • AstraZeneca PLC

Zitieren

APA

Berg, D. D., Docherty, K. F., Talebi, A., Sattar, N., Jarolim, P., Welsh, P., Jhund, P. S., Anand, I. S., DE Boer, R. A., Kato, E. T., Kober, L., Martinez, F. A., O'Meara, E., Ponikowski, P., Schou, M., Solomon, S. D., Hammarstedt, A., McMurray, J. J. V., Sabatine, M. S., & Morrow, D. A. (2026). Growth Differentiation Factor-15 and the Effect of Dapagliflozin in Heart Failure: Insights From the DAPA-HF Trial. Journal of Cardiac Failure, 32(4), 746-757. https://doi.org/10.1016/j.cardfail.2025.07.019

Vancouver

Berg DD, Docherty KF, Talebi A, Sattar N, Jarolim P, Welsh P, et al. Growth Differentiation Factor-15 and the Effect of Dapagliflozin in Heart Failure: Insights From the DAPA-HF Trial. Journal of Cardiac Failure. 2026;32(4):746-757. doi:10.1016/j.cardfail.2025.07.019

BibTeX
@article{Berg2026,
  author = {Berg, David D and Docherty, Kieran F and Talebi, Atefeh and Sattar, Naveed and Jarolim, Petr and Welsh, Paul and Jhund, Pardeep S and Anand, Inderjit S and DE Boer, Rudolf A and Kato, Eri T and Kober, Lars and Martinez, Felipe A and O'Meara, Eileen and Ponikowski, Piotr and Schou, Morten and Solomon, Scott D and Hammarstedt, Ann and McMurray, John J V and Sabatine, Marc S and Morrow, David A},
  title = {Growth Differentiation Factor-15 and the Effect of Dapagliflozin in Heart Failure: Insights From the DAPA-HF Trial},
  journal = {Journal of Cardiac Failure},
  year = {2026},
  volume = {32},
  number = {4},
  pages = {746--757},
  doi = {10.1016/j.cardfail.2025.07.019}
}
Kostenlos starten →